Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease-Reference-Cited by-同舟云学术

Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease

Published:2016-08-21 Issue:9 Volume:17 Page:1306-1312
ISSN:1444-1586
Container-title:Geriatrics & Gerontology International
language:en
Short-container-title:Geriatr Gerontol Int

Author:

Bando Nobuyasu¹,Nakamura Yu²

Affiliation:

1. Department of Mental Health; Kaisei General Hospital; Kagawa Japan

2. Department of Neuropsychiatry, Faculty of Medicine; Kagawa University; Kagawa Japan

Publisher

Wiley

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ggi.12865/fullpdf

Reference21 articles.

1. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine;Cerbai;Eur J Pharmacol,2007

2. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease;Nakamura;Dement Geriatr Cogn Dis Extra,2015

3. Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats;Yang;Curr Alzheimer Res,2012

4. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months;Darreh-Shori;Neurology,2002

5. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population;Bono;Neurochem Int,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present);Expert Opinion on Therapeutic Patents;2022-06-23

2. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease;Molecular Medicine Reports;2018-03-20